These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 25999375)
1. Pro: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? Specks U Nephrol Dial Transplant; 2015 Jul; 30(7):1083-7. PubMed ID: 25999375 [TBL] [Abstract][Full Text] [Related]
2. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC; J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429 [TBL] [Abstract][Full Text] [Related]
3. Con: Should all patients with anti-neutrophil cytoplasmic antibody-associated vasculitis be primarily treated with rituximab? Kronbichler A; Jayne DR Nephrol Dial Transplant; 2015 Jul; 30(7):1075-81. PubMed ID: 25999374 [TBL] [Abstract][Full Text] [Related]
4. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Unizony S; Villarreal M; Miloslavsky EM; Lu N; Merkel PA; Spiera R; Seo P; Langford CA; Hoffman GS; Kallenberg CM; St Clair EW; Ikle D; Tchao NK; Ding L; Brunetta P; Choi HK; Monach PA; Fervenza F; Stone JH; Specks U; Ann Rheum Dis; 2016 Jun; 75(6):1166-9. PubMed ID: 26621483 [TBL] [Abstract][Full Text] [Related]
5. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis. Timlin H; Lee SM; Manno RL; Seo P; Geetha D Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088 [TBL] [Abstract][Full Text] [Related]
9. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab. Cartin-Ceba R; Fervenza FC; Specks U Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095 [TBL] [Abstract][Full Text] [Related]
10. Vasculitis syndromes: RAVE about rituximab in ANCA vasculitis? Tarzi R; Pusey C Nat Rev Nephrol; 2013 Nov; 9(11):628-9. PubMed ID: 24080801 [TBL] [Abstract][Full Text] [Related]
11. Moderator's view: Should all patients with ANCA-associated vasculitis be primarily treated with rituximab? Tesar V Nephrol Dial Transplant; 2015 Jul; 30(7):1088-90. PubMed ID: 25999373 [TBL] [Abstract][Full Text] [Related]
14. Impact of rituximab trials on the treatment of ANCA-associated vasculitis. Alberici F; Jayne DR Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571 [TBL] [Abstract][Full Text] [Related]
15. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Jones RB; Furuta S; Tervaert JW; Hauser T; Luqmani R; Morgan MD; Peh CA; Savage CO; Segelmark M; Tesar V; van Paassen P; Walsh M; Westman K; Jayne DR; Ann Rheum Dis; 2015 Jun; 74(6):1178-82. PubMed ID: 25739829 [TBL] [Abstract][Full Text] [Related]
16. B-cell depleting agents for ANCA vasculitides: a new therapeutic approach. Gómez-Puerta JA; Quintana LF; Stone JH; Ramos-Casals M; Bosch X Autoimmun Rev; 2012 Jul; 11(9):646-52. PubMed ID: 22146313 [TBL] [Abstract][Full Text] [Related]